BackgroundCheck.run
Search For

Jonathan Kern, 331765 Pacific Ave UNIT 2, San Francisco, CA 94109

Related to:
Sara De Guzman Heinz Kern Helga Kern 95

Jonathan Kern Phones & Addresses

San Francisco, CA   

New York, NY   

Philadelphia, PA   

Key Biscayne, FL   

54 Riverside Dr APT 6C, New York, NY 10024    212-7245336   

Work

Company: Heschel, abraham joshua school inc Address: 20 W End Ave, New York, NY 10023 Phones: 212-5957087 Position: Secretary Industries: Elementary and Secondary Schools

Education

Degree: Graduate or professional degree
Get Report
Control this profile

Mentions for Jonathan Kern

Career records & work history

Medicine Doctors

Jonathan W. Kern

Specialties:
Diagnostic Radiology, Musculoskeletal Radiology
Work:
River Ranch Radiology
711 W 38 St STE B7, Austin, TX 78705
512-4549598 (phone) 512-4597449 (fax)
Education:
Medical School
University of Texas Southwestern Medical Center at Dallas
Graduated: 1987
Languages:
English, Spanish
Description:
Dr. Kern graduated from the University of Texas Southwestern Medical Center at Dallas in 1987. He works in Austin, TX and specializes in Diagnostic Radiology and Musculoskeletal Radiology.
Jonathan Kern Photo 1

Jonathan Walter Kern

Specialties:
Radiology
Diagnostic Radiology
Education:
The University of Texas Southwestern (1987)

Publications & IP owners

Us Patents

Method For Identifying Modulators Of The Nrf2-Keap1-Arep Pathway

US Patent:
2010002, Feb 4, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/311644
Inventors:
Jonathan T. Kern - Souderton PA, US
John W. Hess - Lansdale PA, US
Geeta Kandpal - Blue Bell PA, US
Ian J. Reynolds - Collegeville PA, US
International Classification:
G01N 33/53
US Classification:
436501
Abstract:
A method for identifying modulators of the Keap1-NrG-ARE pathway is described. In particular, an assay is described that identifies molecules that inhibit the binding of a labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Molecules that inhibit the binding are activators of the Keap 1-Nrf2-ARE pathway. Activation of the Keap 1-Nrf2-ARE pathway may result in an increased accumulation of Nrf2 and the subsequent induction of protective enzymes, for example, the phase 2 detoxification enzymes. Activators of the Keap1-NrG-ARE pathway are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke.

Leucine-Rich Repeat Kinase Enzyme Activity

US Patent:
2013029, Nov 7, 2013
Filed:
Oct 25, 2011
Appl. No.:
13/880992
Inventors:
John A. McCauley - Maple Glen PA, US
Hemaka A. Rajapakse - Wyncote PA, US
Thomas J. Greshock - Collegeville PA, US
John Sanders - Philadelphia PA, US
Boyoung Kim - Lansdale PA, US
Vanessa L. Rada - Hatfield PA, US
Jonathan T. Kern - Souderton PA, US
Heather H. Stevenson - Ardmore PA, US
Mark T. Bilodeau - Lansdale PA, US
International Classification:
C07D 495/04
C07D 495/10
US Classification:
5142338, 546114, 514301, 546 18, 514278, 544127
Abstract:
Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO—, —O— or NR—, wherein Rac is H, or Calkyl and Rthrough Rare defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.

Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity

US Patent:
2013033, Dec 19, 2013
Filed:
Feb 23, 2012
Appl. No.:
14/000982
Inventors:
John A. McCauley - Maple Glen PA, US
Thomas J. Greshock - Collegeville PA, US
John Sanders - Collegeville PA, US
Heather H. Stevenson - Conshohocken PA, US
Jonathan T. Kern - Souderton PA, US
Ronald K. Chang - Oreland PA, US
International Classification:
C07D 409/14
C07D 417/14
C07F 7/10
C07D 409/04
US Classification:
514 63, 5483644, 514406, 548136, 514363, 548110, 5142102, 544371, 51425407, 544140, 5142335, 5462754, 514337, 546202, 514324
Abstract:
Disclosed are compounds of Formula I: and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO—, —O— or NR, and R, and Rthrough Rare defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.

Possible Relatives

Cynthia M Kern  David A Kern  Dawn Kern  Dean M Kern  Dale D Kern  Debbie A Kern  Deborah S Kern  Jonathan L Johnson  Jonathan A Stancil  Jonathan Standridge 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.